SCHEMBL22492035

SCHEMBL22492035

O=C1CCCC(O)=C1c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.46
ALDH1A1 P00352 4/20 0.45
LMNA P02545 3/20 0.45
MAPT P10636 3/20 0.45
KDM4E B2RXH2 3/20 0.45
POLB P06746 2/20 0.45
HPGD P15428 2/20 0.45
HSD17B10 Q99714 2/20 0.45
TP53 P04637 1/20 0.45
PKM P14618 1/20 0.45
ALOX15 P16050 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
APOBEC3A P31941 1/20 0.44
APOBEC3G Q9HC16 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
HTT P42858 1/20 0.40
PTGS1 P23219 1/20 0.40
PTGS2 P35354 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL979579 0.79 PTGS2 (0.54) ALDH1A1LMNAKDM4EHPGDHSD17B10
SCHEMBL22492006 0.76 KMT2A (0.40) ALDH1A1LMNAKDM4EHPGDHSD17B10
SCHEMBL8384573 0.76 KMT2A (0.40) ALDH1A1LMNAKDM4EHPGDHSD17B10
SCHEMBL22679771 0.76 BRD4 (0.46) ALDH1A1LMNAKDM4EPOLBHPGD
SCHEMBL16432459 0.73 ALDH1A1 (0.42) ALDH1A1LMNAKDM4EHPGDHSD17B10
SCHEMBL8517494 0.72 PTGS1 (0.40) ALDH1A1LMNAKDM4EHPGDHSD17B10
SCHEMBL29280849 0.72 PTGS2 (0.44) ALDH1A1LMNAKDM4EHPGDHSD17B10
Biphenyl SCHEMBL27725627 0.71 ALDH1A1 (0.50) SMN1; SMN2ALDH1A1LMNAMAPTKDM4E
SCHEMBL19335657 0.71 KMT2A (0.50) ALDH1A1KMT2APTGS1PTGS2P2RX7
SCHEMBL978197 0.70 PTGS2 (0.68) KMT2APTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11332472-B2 Substituted piperidines as inhibitors of ubiquitin specific protease 7 LES LABORATOIRES SERVIER (FR) 2022-05-17 US disclosed
US-20200407363-A1 NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 LES LABORATOIRES SERVIER (FR) 2020-12-31 US disclosed
EP-3717482-A1 NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 Les Laboratoires Servier SAS (FR) 2020-10-07 EP disclosed
CN-111542524-A Novel piperidinyl derivatives as inhibitors of ubiquitin-specific protease 7 法国施维雅药厂 2020-08-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11332472-B2 Substituted piperidines as inhibitors of ubiquitin specific protease 7 USP7, PSMA7, PSMB7 SMN1; SMN2 2178/4885ALDH1A1 1391/4885LMNA 1633/4885
US-20200407363-A1 NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 PSMB7, PSMA7, USP7 SMN1; SMN2 2886/4885ALDH1A1 1589/4885LMNA 1863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.